Revisiting Azithromycin for Intermittent Preventive Treatment in Pregnancy

Roh, Michelle E., Unger, Holger and Oldenburg, Catherine (2025) 'Revisiting Azithromycin for Intermittent Preventive Treatment in Pregnancy'. The American Journal of Tropical Medicine and Hygiene, Vol 112, Issue 4, pp. 719-720.

Text tpmd-article-10.4269-ajtmh.24-0734.pdf - Accepted Version Available under License Creative Commons Attribution. Download (546kB)

Abstract

In malaria-endemic regions of Africa, the World Health
Organization recommends pregnant women receive inter�mittent preventive treatment in pregnancy (IPTp), which
entails providing full treatment courses of a long-acting anti�malarial from the second trimester to delivery, with doses
given at least one month apart.1 Sulfadoxine-pyrimethamine
(SP) is the only antimalarial currently recommended for IPTp,
but its antimalarial efficacy is threatened by the emergence
and spread of SP resistance. Azithromycin (AZ) has been
considered as a potential partner drug for IPTp, with the aim
of strengthening antimalarial protection while also impacting
on other factors associated with adverse birth outcomes.
Several clinical trials of AZ-containing IPTp regimens have
been conducted, including combinations of AZ with SP,2-5
chloroquine,6 dihydroartemisinin-piperaquine (DP),7 pipera�quine,8 and trimethroprim-sulfamethoxazole

Item Type:	Article
Subjects:	WB Practice of Medicine > WB 102.5 Clinical medicine - evidence-based practice WQ Obstetrics > Pregnancy Complications > WQ 240 Pregnancy complications (General)
Faculty: Department:	Clinical Sciences & International Health > Clinical Sciences Department
Digital Object Identifer (DOI):	https://doi.org/10.4269/ajtmh.24-0734
SWORD Depositor:	JISC Pubrouter
Depositing User:	JISC Pubrouter
Date Deposited:	12 Mar 2025 13:11
Last Modified:	10 Apr 2025 13:28
URI:	https://archive.lstmed.ac.uk/id/eprint/26176

Statistics

View details

Actions (login required)

Edit Item